Cornell Institute of Biotechnology Services and COVID-19

Cornell University has implemented a number of measures to protect the health, safety and well-being of our community in response to the COVID-19 pandemic.  The Cornell Institute of Biotechnology and associated BRC core facilities are moving to suspend operations as part of a University-wide move to cease all non-essential research activities beyond those activities essential to ensure a return to full operation in the future. All laboratory services beyond those essential activities will be suspended by Wednesday March 18, 2020.

  

All of our services and facilities will be impacted.  The specific impacts will vary by facility and service and will include no physical sample submission, increased turn-around time for samples already submitted, no access to in-person/user-operated instrumentation, delays in the advancement of large projects, and a reliance of phone and online and e-mail communication for consultations in lieu of face to face meetings. More specific information will be shared on a per-service basis or with specific facility users whose work is impacted.

 

For up-to-date information on Cornell University’s status and response to the COVID-19 pandemic, please see the University’s COVID-19 Resources and updates web site.

 

Bioinformatics Facility
Biotechnology Development Facility
Biotechnology Resource Center (BRC)
CAT
Flow Cytometry Facility
Genomics Facility
Imaging Facility
Institute of Biotechnology
Metabolomics Facility
Proteomics Facility